Literature DB >> 21079659

Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients.

Mehri Maleki1,2, Mohammad Sayyah3, Fatemeh Kamgarpour1,4, Morteza Karimipoor1, Aida Arab1, Anahita Rajabi1, Kourosh Gharagozli5, Ahmad Reza Shamshiri6, Esmaeil Shahsavand Ananloo7.   

Abstract

BACKGROUND: One third of epileptic patients are resistant to several anti-epileptic drugs (AED). P-glycoprotein (P-gp) is an efflux transporter encoded by ATP-binding cassette subfamily B member 1 (ABCB1) gene that excludes drugs from the cells and plays a significant role in AEDs resistance. Over-expression of P-gp could be a result of polymorphisms in ABCB1 gene. We studied the association of T129C and T1236C single-nucleotide polymorphisms (SNP) of ABCB1 gene with drug-resistant epilepsy in Iranian epileptics.
METHODS: DNA samples were obtained from 200 healthy controls and 332 epileptic patients, of whom 200 were drug responsive and 132 drug resistant. The frequencies of the genotypes of the two SNP were determined by polymerase chain reaction followed by restriction fragment length polymorphism.
RESULTS: No significant association was found between T129C and T1236C genotypes and drug-resistant epilepsy neither in adults nor in children. However, the risk of drug resistance was higher in female patients with 1236CC (P = 0.02) or CT (P = 0.008) genotype than in those with TT genotype. The risk of drug resistance was also higher in patients with symptomatic epilepsies with 1236CC (P = 0.02) or CT (P = 0.004) genotype than in those with TT genotype. The risk of drug resistance was lower in patients with idiopathic epilepsies with 129TT genotype (P = 0.001) than in those with CT genotype.
CONCLUSION: Our results indicate that T1236C polymorphism is associated with drug resistance in Iranian female epileptic patients. Replication studies with large sample sizes are needed to confirm our results.

Entities:  

Keywords:  ATP-binding cassette subfamily B member 1; Drug-resistant epilepsy; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2010        PMID: 21079659      PMCID: PMC3904059     

Source DB:  PubMed          Journal:  Iran Biomed J        ISSN: 1028-852X


  22 in total

Review 1.  Mechanisms of antiepileptic drug resistance.

Authors:  Sanjay M Sisodiya
Journal:  Curr Opin Neurol       Date:  2003-04       Impact factor: 5.710

2.  ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

Authors:  Takayuki Seo; Takateru Ishitsu; Nao Ueda; Naoyuki Nakada; Keigo Yurube; Kentaro Ueda; Kazuko Nakagawa
Journal:  Pharmacogenomics       Date:  2006-06       Impact factor: 2.533

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response.

Authors:  Chin-Chuan Hung; John Jen Tai; Chun-Jung Lin; Ming-Jen Lee; Horng-Huei Liou
Journal:  Pharmacogenomics       Date:  2005-06       Impact factor: 2.533

Review 5.  Clinical aspects and biological bases of drug-resistant epilepsies.

Authors:  G Regesta; P Tanganelli
Journal:  Epilepsy Res       Date:  1999-04       Impact factor: 3.045

6.  In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats.

Authors:  H Potschka; W Löscher
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

7.  Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.

Authors:  Luca Cucullo; Mohammed Hossain; Ed Rapp; Toby Manders; Nicola Marchi; Damir Janigro
Journal:  Epilepsia       Date:  2007-02-22       Impact factor: 5.864

8.  Several major antiepileptic drugs are substrates for human P-glycoprotein.

Authors:  Carlos Luna-Tortós; Maren Fedrowitz; Wolfgang Löscher
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

Review 9.  The clinical impact of pharmacogenetics on the treatment of epilepsy.

Authors:  Wolfgang Löscher; Ulrich Klotz; Fritz Zimprich; Dieter Schmidt
Journal:  Epilepsia       Date:  2008-07-08       Impact factor: 5.864

10.  MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion.

Authors:  Wolfgang Löscher; Norman Delanty
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

View more
  11 in total

Review 1.  Precision medicine in women with epilepsy: The challenge, systematic review, and future direction.

Authors:  Yi Li; Sai Zhang; Michael P Snyder; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2021-03-25       Impact factor: 2.937

Review 2.  The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review.

Authors:  Wefa Boughrara; Amina Chentouf
Journal:  Acta Neurol Belg       Date:  2022-03-24       Impact factor: 2.471

3.  The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies.

Authors:  Hui Li; Bing Wang; Cheng Chang; Minghua Wu; Yun Xu; Yajun Jiang
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment.

Authors:  Fei Sun; Bo-Qiang Cao; Bo Wang; Shi-Qiang Wu; De-Hua Jiang
Journal:  Exp Ther Med       Date:  2016-07-27       Impact factor: 2.447

Review 5.  Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis.

Authors:  Malek Chouchi; Wajih Kaabachi; Hedia Klaa; Kalthoum Tizaoui; Ilhem Ben-Youssef Turki; Lamia Hila
Journal:  BMC Neurol       Date:  2017-02-15       Impact factor: 2.474

Review 6.  Molecular Genetics of Epilepsy: A Clinician's Perspective.

Authors:  Vikas Dhiman
Journal:  Ann Indian Acad Neurol       Date:  2017 Apr-Jun       Impact factor: 1.383

Review 7.  Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Authors:  Renée Dagenais; Kyle John Wilby; Hazem Elewa; Mary H H Ensom
Journal:  Drugs R D       Date:  2017-09

8.  Health-related quality of life after epilepsy surgery: A prospective, controlled follow-up on the Iranian population.

Authors:  Mahmoud Lotfinia; Ehsan Nazari Maloumeh; Sina Asaadi; Mahmoud Omidbeigi; Guive Sharifi; Bahador Asadi
Journal:  Sci Rep       Date:  2019-05-27       Impact factor: 4.379

9.  ABCB1 variants C3435T and T129C are not associated with colorectal cancer risk.

Authors:  Areej M Al Qahtani; Ayat B Al-Ghafari; Huda A Al Doghaither; Anas H Alzahrani; Ulfat M Omar; Sawsan A Rahimulddin
Journal:  Afr Health Sci       Date:  2019-09       Impact factor: 0.927

10.  Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer.

Authors:  Ayat B Al-Ghafari; Areej M Al Qahtani; Suzan N Alturki; Huda A Al Doghaither; Ekramy M Elmorsy; Hanaa M Tashkandi; Atlal M Abusanad; Shadi S Alkhayyat; Ulfat M Omar; Ahmed A Zeeneldin
Journal:  Oncol Lett       Date:  2020-08-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.